I’d like to see this China deal bring in the initial $5 million to end 2020. And then Generex needs to show Ii-key platform allows for rapid development once the company has that money. It’s unfortunate that Generex looks lethargic in moving forward to face a pandemic due to unknowns to overall investors like SEC audits or a deal gone awry. If Generex had BARDA funds they’d be where others are. But the IND can be accepted, a PI named for a Phase I, protocol described, sites chosen, all to show the ball moving down the field. But let’s start with the China deal at the least bringing in $5 mil to help accomplish goals.
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links